List of Excipients in Branded Drug ONDANSETRON HYDROCHLORIDE AND DEXTROSE

Generic Drugs Containing ONDANSETRON HYDROCHLORIDE AND DEXTROSE

Company	Ingredient	NDC	Excipient
West-ward Pharmaceutical Corp	ondansetron hydrochloride and dextrose	0143-9771	CITRIC ACID MONOHYDRATE
West-ward Pharmaceutical Corp	ondansetron hydrochloride and dextrose	0143-9771	DEXTROSE
West-ward Pharmaceutical Corp	ondansetron hydrochloride and dextrose	0143-9771	SODIUM CITRATE
West-ward Pharmaceutical Corp	ondansetron hydrochloride and dextrose	0143-9771	WATER

What are the Most Frequently-Used Excipients in ONDANSETRON HYDROCHLORIDE AND DEXTROSE?

# Of NDCs	Excipient
1	CITRIC ACID MONOHYDRATE
1	DEXTROSE
1	SODIUM CITRATE
1	WATER

Excipient Strategy and Commercial Opportunities for Ondansetron Hydrochloride and Dextrose

Last updated: March 2, 2026

What are the key excipient considerations for this formulation?

The formulation of ondansetron hydrochloride (HCl) with dextrose relies on excipients that improve stability, enhance bioavailability, and meet manufacturing and patient safety standards.

Core excipient functions

• Dextrose: Serves as a stabilizer, preservative, and osmotic agent. It also enhances palatability in injectable solutions.
• Water for Injection: Acts as a solvent.
• Buffering agents: Maintain pH stability, common options include sodium acetate or phosphate buffers.
• Isotonic agents: Dextrose itself helps ensure isotonicity, important for injectable formulations.
• Preservatives: Chlorobutanol or methylparaben may be added to prevent microbial growth.
• pH adjusters: Hydrochloric acid or sodium hydroxide to achieve optimal pH.

Formulation types and excipient strategies

1. Injectable solutions: Require careful pH control (around 4.0 to 4.5), antioxidants to prevent degradation, and isotonicity adjustments with dextrose.
2. Oral formulations: Require excipients that improve taste, stability, and bioavailability. Dextrose is often used as a sweetener and energy source.
3. Lyophilized powders: Utilize excipients like mannitol as bulking agents, with stabilizers to preserve drug activity upon reconstitution.

Regulatory requirements influencing excipient choice

• US FDA and EMA regulations stipulate purity standards and permissible excipients.
• Excipient qualifications must be documented for safety and lot-to-lot consistency.

What are the commercial opportunities linked to excipient strategies?

Marketability enhancements

• Formulations with optimized excipients can extend shelf life, reducing waste and recall risks.
• Patient adherence improves with palatable oral formulations containing dextrose and compatible flavors.
• Injectable formulations with stable excipient systems allow for rapid, reliable administration in clinical settings.

Patent and exclusivity opportunities

• Developing novel excipient combinations or delivery systems can provide patent opportunities.
• Patent extensions are possible when excipient innovation enhances formulation stability or bioavailability.

Manufacturing and cost advantages

• Excipient choices impact raw material costs.
• Compact, stable formulations reduce manufacturing complexity and logistics costs.
• Use of globally approved excipients facilitates regulatory approval across multiple markets.

Differentiation and premium pricing

• Formulations that demonstrate improved stability, reduced side effects, or enhanced bioavailability can command higher prices.
• Added functionalities, such as preservative-free or low-gluten formulations, meet specific patient needs and expand market reach.

Emerging markets and niche segments

• Hospital and clinical formulations require stable, preservative-compatible excipient systems.
• Oral reconstitution kits with dextrose simplify dosing in outpatient settings.
• Increased focus on pediatric and geriatric patient populations influences excipient selection towards safer, well-tolerated excipients.

How are innovative excipient strategies shaping future opportunities?

• Biocompatible and biodegradable excipients: Reduce environmental and safety concerns.
• Nanotechnology-based excipients: Enhance targeted delivery and bioavailability.
• Smart excipients: Enable controlled-release formulations, prolonging therapeutic effects.
• Personalized medicine: Customizable excipient matrices allow tailored dosing regimens.

Summary of excipient options and implications

Excipient Type	Function	Examples	Market Implication
Stabilizers	Improve chemical & physical stability	Dextrose, Mannitol	Extend shelf life, improve formulation reliability
Buffers	Maintain pH	Sodium acetate, Phosphate buffers	Enhance stability, optimize bioavailability
Preservatives	Prevent microbial growth	Methylparaben, Chlorobutanol	Support multi-dose formulations
Tonicity Agents	Ensure isotonicity in injections	Dextrose, Sodium chloride	Improve compatibility with patient tissues
Flavoring agents	Improve palatability (oral products)	Natural flavors, sweeteners	Increase patient compliance

Key Takeaways

• Excipient selection directly influences formulation stability, bioavailability, regulatory compliance, and marketability of ondansetron solutions.
• Optimization of excipients can create opportunities for patenting, extending exclusivity, and commanding premium pricing.
• Innovations in excipient technology, such as biodegradable or controlled-release systems, open avenues for product differentiation.
• Cost management and regulatory approval depend heavily on excipient choice, especially for global product strategies.

FAQs

1. What role does dextrose play in ondansetron formulations?
   Dextrose acts as an osmotic agent, stabilizer, preservative, and energy source. It also improves isotonicity and palatability.

2. Are there patent opportunities related to excipient strategies?
   Yes; novel combinations or delivery systems involving excipients can extend patent protection and market exclusivity.

3. What are regulatory concerns with excipients?
   They must meet safety standards, have documentation of purity, and comply with specific jurisdictional guidelines like those from the FDA or EMA.

4. How can excipient strategies support market expansion?
   Better stability, shelf life, and patient tolerability facilitate entry into new regions and segments, including pediatric or geriatric markets.

5. What emerging excipient technologies could impact future formulations?
   Biodegradable excipients, nanocarriers, controlled-release matrices, and personalized excipient formulations.

Citations

[1] U.S. Food and Drug Administration. (2021). Guidance for Industry: Excipients in Drug Products.
[2] European Medicines Agency. (2019). Excipients in Medicinal Products.
[3] Aulton, M. E., & Taylor, K. M. G. (2013). Pharmaceutics: The Science of Dosage Form Design.
[4] Park, H., & Kim, B. (2020). Excipient strategies for enhancing drug stability and bioavailability. Journal of Pharmaceutical Sciences, 109(4), 1220-1229.